What one share of Arcutis Biotherapeutics holds
We are a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Our current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions.
Arcutis Biotherapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.52 |
|---|---|
| Profit | $0.22 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | $0.30 |
| Cash and investments | $0.27 |
| Debt | $0.87 |
| Book value | $1.76 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$15.53 | $0.00 | −$11.36 | — | −$19.35 |
| 2019 | — | −$22.78 | $0.16 | −$23.40 | — | −$30.66 |
| 2020 | $0.00 | −$3.80 | $0.01 | −$3.18 | — | $6.24 |
| 2021 | $0.00 | −$4.18 | $0.02 | −$3.55 | — | $5.92 |
| 2022 | $0.07 | −$5.66 | $0.01 | −$4.69 | — | $3.43 |
| 2023 | $0.86 | −$3.78 | $0.01 | −$3.57 | — | $0.92 |
| 2024 | $1.62 | −$1.16 | $0.00 | −$0.93 | — | $1.34 |
| 2025 | $2.96 | −$0.13 | $0.01 | −$0.05 | — | $1.54 |
Common questions about Arcutis Biotherapeutics
How much does one share of Arcutis Biotherapeutics earn?
Over the last 12 months, each share of Arcutis Biotherapeutics earned $0.22 of profit on $3.52 of sales, keeping about 6¢ of every $1 (profit margin).
Does Arcutis Biotherapeutics pay a dividend?
Arcutis Biotherapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Arcutis Biotherapeutics’s book value per share?
Arcutis Biotherapeutics’s book value is $1.76 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Arcutis Biotherapeutics have?
Each share of Arcutis Biotherapeutics has $0.27 of cash and investments and $0.87 of debt, as of June 30, 2026.
What is Arcutis Biotherapeutics’s free cash flow per share?
$0.30 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Arcutis Biotherapeutics bought back shares?
Arcutis Biotherapeutics’s share count rose about 10163% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.